Breaking News

WuXi Biologics Recognized as ESG Leader by Morningstar Sustainalytics

Marks the sixth consecutive year that WuXi Biologics has received this honor

Author Image

By: Charlie Sternberg

Associate Editor

WuXi Biologics, a global Contract Research, Development and Manufacturing Organization (CRDMO), has been named by Morningstar Sustainalytics as both an Industry ESG Leader and a Regional ESG Leader for 2026. Marking the sixth consecutive year that WuXi Biologics has received this honor, the recognition highlights the company’s commitment to advancing sustainability throughout its global business operations and value chain and demonstrates the success of its long-term sustainability stra...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters